Beacon Therapeutics Raises $170M Series B
Summary: Beacon Therapeutics secured $170 million in a Series B round to further its gene therapy for retinal diseases.
Founded in 2023, London-based Beacon Therapeutics is advancing AGTC-501, a gene therapy for blindness-causing retinal diseases, in phase 2/3 trials. The funds will support trial continuation and commercialization efforts.
BioAge Files for $100M IPO
Summary: BioAge announced a $100M IPO aiming to list on Nasdaq.
BioAge focuses on developing obesity treatments, with its oral apelin receptor agonist in phase 2 trials. The IPO will help advance clinical trials, including a brain-penetrant NLRP3 inhibitor.
eGenesis Raises $190M in Series D
Summary: eGenesis raised $190 million to further its xenotransplantation research.
eGenesis, working on genetically engineered pig organs for human transplantation, secured $190M to advance its kidney transplant trials and expand production capacity.
Kintara Therapeutics Acquires TuHURA Biosciences
Summary: Kintara Therapeutics acquired TuHURA Biosciences, advancing personalized cancer vaccines.
Kintara’s acquisition of TuHURA Biosciences will facilitate Nasdaq listing and accelerate the development of personalized cancer vaccines to overcome immunotherapy resistance.
Formation Bio Secures $372M Series D
Summary: AI-driven biotech Formation Bio raised $372M to expand its pipeline.
Formation Bio uses AI to automate clinical trial workflows. The Series D will support the acquisition and in-licensing of clinical-stage assets, aiming to improve workflow automation in trials.
